Atrys Health SA (ES:ATRY)
BME:ATRY
Top Page
Atrys Health SA
(BME:ATRY)
Select Model
Select Model
Rating:42Neutral
Price Target:
€3.00
▲(9.49% Upside)
Action:ReiteratedDate:11/22/25
Atrys Health SA's overall stock score is primarily impacted by its financial performance and technical analysis. The company faces significant profitability and liquidity challenges, with bearish technical indicators further weighing on the score. Valuation metrics also suggest the stock is overvalued given its current earnings potential.
Positive Factors
Revenue Growth
Atrys reports consecutive revenue expansion, signaling sustained demand for its oncology, imaging and telemedicine services. Durable top-line growth supports scale economics, strengthens negotiating leverage on contracts, and provides a base for future margin recovery as fixed costs are absorbed.
Negative Factors
Ongoing Losses
Persistent negative EBIT and net losses indicate the company has yet to translate high gross margins into bottom-line profitability. Continued losses constrain retained earnings, limit reinvestment from operating profits, and raise risk around achieving self-sustaining growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Atrys reports consecutive revenue expansion, signaling sustained demand for its oncology, imaging and telemedicine services. Durable top-line growth supports scale economics, strengthens negotiating leverage on contracts, and provides a base for future margin recovery as fixed costs are absorbed.
Read all positive factors
Atrys Health SA (ATRY) vs. iShares MSCI Spain ETF (EWP)
Market Cap
€208.18M
Dividend YieldN/A
Average Volume (3M)83.73K
Price to Earnings (P/E)―
Beta (1Y)0.53
Revenue Growth15.90%
EPS Growth37.03%
CountryES
Employees1,637
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding76,014,190
10 Day Avg. Volume190,561
30 Day Avg. Volume83,732
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)1.01
Price to Sales (P/S)1.20
P/FCF Ratio-25.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€5.00Price Target Upside82.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.21
Revenue Forecast (FY)€199.18M
Atrys Health SA Business Overview & Revenue Model
Company Description
Atrys Health, S.A., a biomedical company, provides diagnostic services and medical treatments. The company offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics; and diagnostic second opinion, test di...
How the Company Makes Money
Atrys Health generates revenue through multiple streams, primarily from its telemedicine and diagnostic imaging services. The company charges healthcare providers and patients for the use of its telehealth platform, which allows for remote consult...
Atrys Health SA Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
55
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 227.00M | 212.74M | 201.57M | 158.37M | 121.01M | 33.81M |
| Gross Profit | 59.30M | 145.38M | 141.77M | 24.20M | 100.89M | 12.40M |
| EBITDA | 27.67M | 19.07M | 31.91M | 16.63M | 5.87M | 6.68M |
| Net Income | -24.59M | -31.77M | -45.59M | -23.15M | -23.20M | -5.55M |
Balance Sheet | ||||||
| Total Assets | 579.13M | 584.19M | 629.00M | 705.28M | 565.63M | 175.78M |
| Cash, Cash Equivalents and Short-Term Investments | 20.58M | 29.29M | 42.18M | 35.84M | 41.70M | 17.60M |
| Total Debt | 193.40M | 166.13M | 254.00M | 241.22M | 154.95M | 71.46M |
| Total Liabilities | 337.61M | 330.95M | 339.12M | 367.71M | 291.65M | 100.45M |
| Stockholders Equity | 241.49M | 253.10M | 289.87M | 337.63M | 274.03M | 71.38M |
Cash Flow | ||||||
| Free Cash Flow | 17.80M | -10.14M | -547.00K | -30.59M | -3.87M | -6.69M |
| Operating Cash Flow | 23.28M | 3.00M | 5.70M | -15.43M | 4.69M | -1.40M |
| Investing Cash Flow | -11.95M | -12.95M | 395.00K | -80.59M | -2.45M | -52.08M |
| Financing Cash Flow | -18.90M | -11.51M | 8.19M | 94.77M | 14.08M | 62.63M |
Atrys Health SA Technical Analysis
Negative
2.74
Price Trends
2.92
Negative
2.87
Negative
2.89
Negative
Market Momentum
-0.05
Positive
42.90
Neutral
43.02
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ES:ATRY, the sentiment is Negative. The current price of 2.74 is below the 20-day moving average (MA) of 2.80, below the 50-day MA of 2.92, and below the 200-day MA of 2.89, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 42.90 is Neutral, neither overbought nor oversold. The STOCH value of 43.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ES:ATRY.
Atrys Health SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | €215.25M | 9.43 | ― | 3.37% | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | €201.73M | 41.66 | 2.03% | 1.91% | -1.19% | -54.66% | |
46 Neutral | €211.33M | -88.77 | -2.58% | ― | ― | 36.23% | |
42 Neutral | €208.18M | -5.25 | -9.43% | ― | 15.90% | 37.03% |
* Healthcare Sector Average
ES:ATRY
Atrys Health SA
2.74
-0.26
-8.67%
ES:RJF
LABORATORIO REIG JOFRE
2.47
-0.15
-5.54%
ES:ORY
Oryzon Genomics SA
2.68
-0.51
-15.99%
ES:BST
ADL Bionatur Solutions SA
0.23
-0.09
-28.17%
ES:PRM
PRIM, S.A.
12.70
3.01
31.10%
ES:LAB
Labiana Health SA
4.84
1.99
70.12%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.